Rocket Pharmaceuticals Inc
RCKTHealthcare|Biotechnology|USA
$3.91
-0.28 (-6.68%)
Tangible Book
$1.59
Earnings Power
$0.30
Financials
Financial Snapshot
Market Cap
$426.9M
Enterprise Value
$119.6M
Revenue (TTM)
$0.00
Net Income (TTM)
$-209.4M
Cash & Equivalents
—
Net Cash/Share
$0.89
Free Cash Flow (TTM)
$-179.8M
Operating CF (TTM)
$-179.6M
Debt/Equity
0.1
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$44.9M
Monthly Burn
$15.0M
Est. Runway
—
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $126.5M | $100.0M | $205.7M | $304.1M | $482.7M | $388.7M | $356.4M | $373.2M | $372.3M | $188.9M | $144.4M | |
| Operating Cash Flow | $-37.3M | $-26.1M | $-53.8M | $-64.7M | $-74.6M | $-121.2M | $-178.1M | $-194.9M | $-209.7M | $-190.0M | $-179.6M | |
| Free Cash Flow | $-37.8M | $-26.2M | $-55.2M | $-87.9M | $-103.7M | $-128.9M | $-186.8M | $-211.4M | $-215.6M | $-190.5M | $-179.8M | |
| Capital Expenditure | $-487.0K | $-70.0K | $-1.5M | $-23.3M | $-29.1M | $-7.7M | $-8.6M | $-16.5M | $-5.9M | $-440.0K | $-169.0K | |
| Financing Cash Flow | $53.1M | $19.0K | $153.5M | $177.8M | $283.0M | $37.7M | $155.3M | $208.4M | $185.7M | $148.0K | $147.0K |
R&D Spending
R&D (TTM)
$137.5M
R&D Intensity
—
R&D Growth YoY
-3.2%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $32.0M | $14.2M | $53.3M | $57.9M | $105.4M | $125.5M | $165.6M | $186.3M | $171.2M | $142.0M | $137.5M | |
| R&D % of Revenue | — | — | — | — | — | — | — | — | — | — | — | |
| SG&A | $9.9M | $12.5M | $17.9M | $18.2M | $28.9M | $41.8M | $58.8M | $73.3M | $102.0M | $86.5M | $75.1M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $32.0M | $14.2M | $53.3M | $57.9M | $105.4M | $125.5M | $165.6M | $186.3M | $171.2M | $142.0M | $137.5M | |
| SG&A | $9.9M | $12.5M | $17.9M | $18.2M | $28.9M | $41.8M | $58.8M | $73.3M | $102.0M | $86.5M | $75.1M | |
| Operating Income | $-41.9M | $-26.7M | $-71.0M | $-75.9M | $-134.3M | $-166.2M | $-223.8M | $-259.7M | $-273.2M | $-228.5M | $-212.6M | |
| Interest Expense | $-1.4M | $-3.6M | $-5.2M | $-6.0M | $-7.5M | $-5.9M | $-1.9M | $-1.9M | $-1.9M | $-1.9M | $-1.9M | |
| Pretax Income | $-42.9M | $-29.5M | $-74.5M | $-77.3M | $-139.7M | $-169.1M | $-221.9M | $-245.6M | $-258.7M | $-223.1M | $-209.4M | |
| Net Income | $-42.9M | $-29.5M | $-74.5M | $-77.3M | $-139.7M | $-169.1M | $-221.9M | $-245.6M | $-258.7M | $-223.1M | $-209.4M | |
| EPS (Diluted) | -6.41 | -4.36 | -1.89 | -1.58 | -2.52 | -2.67 | -3.26 | -2.92 | -2.73 | -2.01 | -1.87 | |
| EBITDA | $-41.3M | $-25.7M | $-69.0M | $-70.9M | $-125.9M | $-157.8M | $-213.7M | $-236.6M | $-247.5M | $-210.2M | $-197.3M | |
| Shares Out. (M) | 6.68 | 6.76 | 39.38 | 49.01 | 55.38 | 63.23 | 68.15 | 84.01 | 94.81 | 111.12 | 112.13 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $29.8M | $78.7M | $111.4M | $185.4M | $297.1M | $232.7M | $140.5M | $55.9M | $163.6M | $77.6M | $49.6M | |
| Marketable Securities | $96.7M | $21.3M | $94.4M | $118.7M | $185.6M | $156.0M | $215.9M | $317.3M | $208.7M | $111.4M | $94.8M | |
| Total Current Assets | $128.3M | $101.0M | $209.1M | $307.8M | $487.3M | $392.1M | $364.1M | $378.2M | $378.2M | $192.7M | $149.8M | |
| Total Assets | $129.6M | $101.8M | $251.3M | $372.1M | $590.8M | $497.0M | $551.8M | $566.3M | $527.7M | $330.4M | $285.4M | |
| Total Current Liabilities | $7.0M | $4.1M | $15.4M | $18.3M | $32.6M | $22.2M | $39.2M | $48.5M | $40.7M | $30.2M | $24.5M | |
| Long-Term Debt | $49.0M | $49.5M | $41.4M | $45.0M | $35.1M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $56.5M | $54.0M | $57.3M | $64.8M | $87.3M | $42.3M | $62.1M | $73.8M | $64.5M | $53.2M | $47.4M | |
| Stockholders' Equity | $73.2M | $47.8M | $194.0M | $307.3M | $503.5M | $454.7M | $489.7M | $492.6M | $463.2M | $277.2M | $238.0M | |
| Retained Earnings | $-238.9M | $-268.4M | $-105.9M | $-183.1M | $-322.8M | $-491.9M | $-713.8M | $-959.4M | $-1.22B | $-1.44B | $-1.49B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-37.3M | $-26.1M | $-53.8M | $-64.7M | $-74.6M | $-121.2M | $-178.1M | $-194.9M | $-209.7M | $-190.0M | $-179.6M | |
| Capital Expenditure | $-487.0K | $-70.0K | $-1.5M | $-23.3M | $-29.1M | $-7.7M | $-8.6M | $-16.5M | $-5.9M | $-440.0K | $-169.0K | |
| Free Cash Flow | $-37.8M | $-26.2M | $-55.2M | $-87.9M | $-103.7M | $-128.9M | $-186.8M | $-211.4M | $-215.6M | $-190.5M | $-179.8M | |
| Investing Cash Flow | $-66.1M | $75.0M | $-5.3M | $-39.0M | $-96.6M | $18.9M | $-69.3M | $-98.1M | $131.7M | $103.8M | $179.3M | |
| Financing Cash Flow | $53.1M | $19.0K | $153.5M | $177.8M | $283.0M | $37.7M | $155.3M | $208.4M | $185.7M | $148.0K | $147.0K | |
| Issuance of Stock | $4.0M | $0.00 | $154.0M | $178.1M | $281.4M | $37.7M | $155.3M | $208.4M | $185.7M | $0.00 | $-215.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $-668.0K | $0.00 | $-72.0K | $0.00 | $-47.0K | $0.00 | $0.00 | $-67.0K | $-67.0K | |
| Issuance of Debt | $52.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $-3.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-1.0K | |
| Stock Based Comp. | $2.9M | $4.0M | $13.6M | $13.4M | $18.6M | $29.2M | $31.0M | $39.4M | $43.9M | $37.1M | $35.2M | |
| Net Change in Cash | $-50.2M | $48.9M | $94.4M | $74.1M | $111.8M | $-64.6M | $-92.2M | $-84.6M | $107.7M | $-86.1M | $-221.0K |
Dilution Tracker
Shares outstanding grew 77.3% over 5 years — significant dilution
Shares Outstanding
112M
5-Year Share Growth
+77.3%
Stock Issuance (TTM)
$-215.0K
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 6.68 | 6.76 | 39.38 | 49.01 | 55.38 | 63.23 | 68.15 | 84.01 | 94.81 | 111.12 | 112.13 | |
| YoY Change % | — | 1.2% | 482.1% | 24.5% | 13.0% | 14.2% | 7.8% | 23.3% | 12.9% | 17.2% | 0.9% | |
| Stock Issuance | $4.0M | $0.00 | $154.0M | $178.1M | $281.4M | $37.7M | $155.3M | $208.4M | $185.7M | $0.00 | $-215.0K | |
| Stock Repurchase | $0.00 | $0.00 | $-668.0K | $0.00 | $-72.0K | $0.00 | $-47.0K | $0.00 | $0.00 | $-67.0K | $-67.0K | |
| Stock Based Comp. | $2.9M | $4.0M | $13.6M | $13.4M | $18.6M | $29.2M | $31.0M | $39.4M | $43.9M | $37.1M | $35.2M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| ROE % | -47.1% | -48.8% | -61.6% | -30.8% | -34.5% | -35.3% | -47.0% | -50.0% | -54.1% | -60.3% | -65.6% | |
| ROA % | -35.3% | -25.5% | -42.2% | -24.8% | -29.0% | -31.1% | -42.3% | -43.9% | -47.3% | -52.0% | -55.8% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S—
Historical— / — / —
Industry Med.9.49
P/B1.79
Historical— / — / 1.79
Industry Med.2.93
EV/EBITDA-1.56
Historical-1.56 / — / —
Industry Med.13.02
EV/Revenue—
Historical— / — / —
Industry Med.8.59
P/FCF—
Historical— / — / —
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$1.59
Net Current Assets
$0.940
Net-Net Working Capital
$0.89
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | - | - | - | - | - | - | 0.00 | |
| PB Ratio | 2.25 | 1.49 | 3.45 | 4.06 | 6.64 | 3.10 | 3.16 | 5.49 | 2.89 | 1.37 | 1.79 | |
| EV/EBITDA | -2.11 | -0.80 | -7.33 | -13.96 | -23.22 | -6.60 | -5.69 | -9.96 | -4.01 | -1.03 | -1.56 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
—
Distress
Piotroski F-Score
2
Weak
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $2.51M | $23.12M | $69.19M |
| Net Income | $-111.52M | $-179.48M | $-191.93M |
| EPS | -0.93 | -1.48 | -1.34 |
| Book Value per Share | 3.56 | 2.25 | 1.65 |
| Operating Cash Flow per Share | 0.21 | -1.16 | -0.67 |
| Operating CF | $22.99M | $-129.52M | $-75.13M |